Roche’s Vismodegib Meets Main Goal of Advanced Skin-Cancer Study
Roche Holding AG (ROG)’s experimental vismodegib treatment helped patients with a form of skin cancer known as advanced basal cell carcinoma, according to a study presented today at the European Multidisciplinary Cancer Congress in Stockholm.
The drug shrunk tumors and healed lesions in patients whose cancer had progressed too far to be removed with surgery, Roche said in a statement Sept. 12.
To contact the reporter on this story: Kristen Hallam in London at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com